EZZ
EZZ LIFE FPO [EZZ]
Healthcare · ASX Small Cap
$1.2800 -16.9%
Updated 2026-03-02 · Scores refresh every scan
Appeared in 2 consecutive scans→ Score +1First seen: 2026-02-25
Score Breakdown
Technical34
Catalyst53
Sentiment50
Fundamental82
Momentum48
Risk Gate50
Active Signals
Bullish Signals
- RSI oversold (potential bounce)
- Stochastic oversold
- Price at lower Bollinger Band (oversold)
- Sustained volume spike (2.1x median) on DOWN trend
- Sharp 5-day decline (-14.4%)
- Volatility contracting (breakout setup)
- Cash positive / operating cashflow positive
- 4C filed 2026-01-30
- Low P/S ratio (1.1x)
- Revenue in sharp decline (-18%)
- EPS estimates revised upward (+10pts)
- Near 52-week low (12% of range)
- Small-cap ($20-100M)
- Earnings in sharp decline (-39% QoQ)
- CANSLIM A: Strong annual earnings CAGR (72%)
- CANSLIM S: Tight float (28%)
- Strong return on equity (27%)
- Analyst EPS expectations rising (+61%)
- ASX200 bullish (+1.5% 5d)
- RBA cutting (+2pts)
Risk Signals
- MACD momentum weakening
- Price below MAs (downtrend)
- Breakdown below 20-day support
- Below 200-day MA (long-term downtrend)
- Post-earnings drift: negative surprise (SUE -5)
- Insufficient sentiment data (defaulting to neutral)
- Neutral/mixed sentiment
- Earnings momentum negative
- Revenue momentum declining (-18%)
Recent Catalysts
NONE Half Yearly Report and Accounts
NONE EZZ Appoints Aumake in $10m Exclusive Distributor Agreement
NONE $10m Exclusive Distribution Agreement with EZZ Life Sciences
LOW Quarterly Activities/Appendix 4C Cashflow Report
Announcement tone +3pts
Recent ASX Announcements
| 2026-02-27 | Half Yearly Report and Accounts PRICE SENSITIVE |
| 2026-02-16 | EZZ Appoints Aumake in $10m Exclusive Distributor Agreement PRICE SENSITIVE |
| 2026-02-16 | $10m Exclusive Distribution Agreement with EZZ Life Sciences PRICE SENSITIVE |
| 2026-01-30 | Quarterly Activities/Appendix 4C Cashflow Report PRICE SENSITIVE |
| 2026-01-21 | Initial Director's Interest Notice x 3 |
Key Metrics
$72.4M
Market Cap
22K
Avg Volume
2.1x
Vol Ratio
$1.29 — $3.38
52-Week Range
N/A
Short Interest
N/A
Cash Runway
27.2%
ROE
10.1%
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: -39% |
| A | Annual Earnings | pass | CAGR: 72% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | pass | Float: 28% |
| L | Leader vs Laggard | laggard | RS: -4 |
| I | Institutional Sponsorship | weak | Inst: 1% |
| M | Market Direction | pass | Bullish |
Sector: Healthcare
Ranked #90 of 119 · Sector avg: 51
View all Healthcare signals →